http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Unstructured Information Management Projects at IBM Tokyo Research Laboratory
Takeda, Koichi,Watanabe, Hideo,Uramoto, Naohiko,Nomiyama, Hiroshi,Matsuzawa, Hirofumi,Nasukawa, Tetsuya,Nagano, Tohru,Murakami, Akiko,Takeuchi, Hironori,Kanayama, Hiroshi,Kobayashi, Mei,Aono, Masaki,I 한국정보처리학회 2004 정보처리학회지 Vol.11 No.2
A Study on Ship’s Autopilot System for a Small Boat
Toshihiko NAKATANI,Makoto ENDO,Keiji SASAYA,Takashi MIWA,Hiroshi MIKAMI,Taizo KANEDA,Emi KANAYAMA,Erika URA 제어로봇시스템학회 2011 제어로봇시스템학회 국제학술대회 논문집 Vol.2011 No.10
This paper describes dynamics analysis of a small training boat and the application of a gain map PID controller to the autopilot of the vessel. After upgrading the autopilot of the Sazanami, an actual small training boat, in order to identify the boat model, zigzag maneuver trials were performed at various speeds. It was found that the Nomoto gain and time constant changed considerably with the vessel’s speed. Based on this analysis, an improved autopilot system that utilizes a gain map PID controller to compensate for vessel maneuverability changes was designed. From the results of various control simulations, we determined that the proposed system offered significant performance improvements over the vessel’s conventional autopilot.
Naoto Furukawa,Yoshikazu Sasaki,Aiko Shigemitsu,Juria Akasaka,Seiji Kanayama,Ryuji Kawaguchi,Hiroshi Kobayashi 대한부인종양학회 2013 Journal of Gynecologic Oncology Vol.24 No.2
Objective: In the present study, we evaluated changes in CA-125 cut-off values predictive of complete interval debulking surgery (IDS) after neoadjuvant chemotherapy (NAC) using receiver operating characteristic (ROC) analysis. Methods: This retrospective single-institution study included patients with International Federation of Gynecology and Obstetrics (FIGO) stage III epithelial ovarian cancer and a pre-NAC serum CA-125 level of greater than 40 U/mL who were treated with neoadjuvant platinum-based chemotherapy followed by IDS between 1994 and 2009. Logistic regression analysis was used to evaluate univariate and independent multivariate associations with the effect of clinical, pathological, and CA-125 parameters on complete IDS, and ROC analysis was used to determine potential cut-off values of CA-125 for prediction of the possibility of complete IDS. Results: Seventy-five patients were identified. Complete IDS was achieved in 46 (61.3%) patients and non-complete IDS was observed 29 (38.7%). Median pre-NAC CA-125 level was 639 U/mL (range, 57 to 6,539 U/mL) in the complete IDS group and 1,427 U/mL (range, 45 to 10,989 U/mL) in the non-complete IDS group. Median pre-IDS CA-125 level was 15 U/mL (range, 2 to 60 U/mL) in the complete IDS group and 53 U/mL (range, 5 to 980 U/mL) in the non-complete IDS group (p<0.001). Multivariate analyses performed with complete IDS as the endpoint revealed only pre-IDS CA-125 as an independent predictor. The odds ratio of non-complete IDS was 10.861 when the pre-IDS CA-125 level was greater than 20 U/mL. Conclusion: The present data suggest that in the setting of IDS after platinum-based NAC for advanced ovarian cancer, a pre-IDS CA-125 level less than 20 U/mL is an independent predictor of complete IDS.